Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor. Tanya B. Dorff, MD, medical oncologist and ...
Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced gastric and gastroesophageal cancers. New research presented at ASCO GI positions ...
A statistically significant OS benefit was observed with relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer. The 48-month OS rate was 78.6% with pembrolizumab vs 60.4 ...
Updated data from the ASC4FIRST trial affirm asciminib as the treatment of choice for many patients with chronic myeloid leukemia in chronic phase. Experts discuss abstracts from the 2026 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results